The FDA has now started a review of the highly anticipated drug, and AZ is using a priority review voucher to shorten the ...
The FDA estimates that a typical nonclinical programme with a monoclonal antibody product could include more than 100 NHPs, ...
VTx-002 is described as a first-in-class vectorised antibody targeting molecular pathways involving TAR DNA-binding protein ...
Consistency is another. HCPs are increasingly accustomed to seamless digital experiences in other areas of their professional ...
Bender discusses the possibility of shifting the oncological treatment paradigm with intra-tumourally injected therapeutics, ...
The federal appeals court has now reversed the 2022 verdict upholding the '039 patent, thereby vacating the Texas court's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback